Endo, Y., Oka, A., Uehara, A., et al. (2020) Fatal Case of Toxic Epidermal Necrolysis Due to Apalutamide Used as a Novel Prostate Cancer Drug. The Journal of Dermatology, 47, e359-e360.
https://doi.org/10.1111/1346-8138.15510

has been cited by the following article:

• TITLE: Enzalutamide Associated with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Overlap: A Case Report

  AUTHORS: Sharjeel Israr, Christopher R. Mellon, Hayley J. Springs, Asia N. Quan, Marc R. Matthews

  KEYWORDS: Prostate Cancer, Enzalutamide, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, SJS/TEN

  JOURNAL NAME: Surgical Science, Vol.12 No.12, December 31, 2021

  ABSTRACT: Enzalutamide is a hormonal therapy that blocks the action of androgens, such as testosterone in the treatment of metastatic castration-resistant prostate cancer. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) overlap and are part of an adverse drug reaction continuum of disease, in which there is a 10% - 30% involvement of the skin surface with mucositis, blisters, skin slough, and a macular rash. A 66-year-old male was treated with enzalutamide for metastatic prostate cancer and developed SJS/TEN overlap with 25% total body surface area skin involvement. The patient received a seven-day course of cyclosporine to which he responded by re-epithelialization but succumbed to multi-organ failure. While SJS/TEN has been reported with apalutamide, to our knowledge, this is the first case of SJS/TEN overlap with enzalutamide.